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Cancer is a major public health prob-
lem in the United States and around the
world with millions of new cases diagnosed
each year. While most of the cancers occur
sporadically, a number of familial cancer
predisposition syndromes have been identi-
fied in recent years. Cancer susceptibility
syndromes are responsible for an estimated
5 to 10 percent of all cancer cases. Genes
responsible for hereditary cancers are often
also mutated in sporadic cancers. Studies
of cellular functions of cancer susceptibility
genes have made an invaluable contribu-
tion to our understanding of tumorigenesis.
Multiple endocrine neoplasia type 1
(MEN1) is an autosomal dominant cancer
predisposition syndrome, the gene for
which encodes a nuclear protein: menin.
The biochemical function of this protein is
largely unknown, but several studies have
shown a role in transcriptional modulation
through interaction with histone deacety-
lases and histone methyltransferases. Tu-
mors in MEN1 arise through a two-hit
mechanism, suggesting that menin either
negatively regulates cell growth or partici-
pates in maintenance of genomic integrity.
In this work, we provide a general
overview of the hereditary cancer syn-
dromes with both dominant and recessive
modeofinheritance.Wethendiscussrecent
advances in understanding the biological
role of MEN1 gene and the mechanisms by




Despite the complexity of cancer as a
disease, there are some common features
shared by all cancer cells that distinguish
them from their normal counterparts. They
are immortal and have a high proliferative
potential. They no longer require external
growth signals to activate the proliferation
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hibitory signals. They have developed
mechanisms for evading senescence and
programmed cell death, or apoptosis. In
order to ensure tumor growth, the cells of
solid tumors must promote the formation of
new blood vessels for oxygen and nutrient
supply. And, finally, malignant cells fail to
exhibit normal cell-cell interactions, which
results in their ability to invade and to
metastasize and grow in an abnormal cellu-
lar environment [1].The acquisition of these
qualities is not a single event but rather the
result of an accumulation of multiple genetic
alterations leading to escape from normal
control of growth regulation and differenti-
ation [2].
Genes with very diverse cellular func-
tionshavebeenimplicatedincarcinogenesis.
This includes genes involved in intracellular
signaling cascades, cell cycle control, cell
differentiation, apoptosis, protein synthesis
and degradation, organization of cytoskele-
ton, cell migration, cell-cell interaction, reg-
ulation of transcription, chromatin
remodeling, and DNA damage sensing and
repair [3-5]. Understanding how the disrup-
tionofthesecellularprocessesleadstotumor
formation is the key to rational development
of effective cancer therapies.
Because the development of cancer is a
multi-step process, it may take years be-
tween the occurrence of the first genetic le-
sion and the actual formation of malignant
neoplasm. Thus, the incidence of cancer in-
creases with age. In rare cases, however, in-
dividuals inherit a mutant allele of a cancer
predisposition gene, which increases the
mutation rate and promotes the development
of cancer.Thus, individuals with cancer pre-
disposition syndromes have both a greater
risk of developing cancer and an average
earlier age of onset compared to the general
population.
In 1971, Knudson proposed his famous
“two-hit” hypothesis [6]. By observing pa-
tients with familial and sporadic retinoblas-
toma, he suggested that individuals with
familial cases inherited the first genetic le-
sion, or “hit,” and that they only needed to
acquire one more hit to develop cancer.
These patients developed retinoblastoma at
an earlier age than individuals with sporadic
tumors who needed to acquire two somatic
hits in the same cell. This hypothesis was
confirmed with the discovery of the
retinoblastoma (RB1) gene in 1986 [7]. In-
deed, individuals with familial retinoblas-
toma inherited a germline mutation in one
allele of the RB1 gene with the remaining
wild type allele being lost in tumors, often
through a process involving large deletions
with loss of heterozygosity (LOH) for sur-
rounding polymorphic loci [7].
Since the discovery of RB1, multiple
tumor-predisposition genes have been iden-
tified by the study of familial cancer syn-
dromes. It is estimated that 5 to 10 percent
of all cancers develop in individuals who
have inherited a mutation conferring cancer
susceptibility [8]. Analysis of the genes re-
sponsible for hereditary cancer predisposi-
tion and the pathways in which they act has
beencriticallyimportantinprovidinginsight
into cancer formation, because the same
genes that are affected in cancer-predisposi-
tion syndromes are often responsible for the
majorityofsomaticcancercasesaswell. For
example, germline mutations in the APC
gene account for less than one percent of all
colorectal cancers, but APC is also inacti-
vatedinnearlyallsporadiccoloncancers[2].
More than 50 cancer predisposition
syndromes have been identified to date [8,
9] with both dominant and recessive modes
of inheritance (Table 1). Activating muta-
tions in oncogenes occur only in a few cases,
such as RETin multiple endocrine neoplasia
type 2 (MEN2) [10] and MET in familial
papillary renal carcinoma [11]. Activated
oncogenes function dominantly in the cell,
and mutation of the second allele is not re-
quired. Most of the dominantly inherited
cancer syndromes, however, have an inacti-
vating mutation in a tumor suppressor, and
disease formation follows the two-hit rule.
The first hit is a germline mutation that ex-
ists in every cell of the body. Somatic inac-
tivation of the second allele of the same
locus in certain tissues may initiate neoplas-
tic transformation. Thus, cancer predisposi-
tion syndromes often have dominant mode
106 Busygina and Bale: MEN1 as a cancer predisposition syndromeof inheritance at the level of the organism,
but at the cellular level they are recessive be-
cause inactivation of both copies of the gene
is required for cancer formation.
Genes whose inactivation leads to tu-
morigenesis are divided into two distinct
groups: gatekeepers and caretakers. Gate-
keepers are usually “classical” tumor sup-
pressors that directly regulate cell growth,
differentiation, and death in certain tissues.
Dysregulation of a gatekeeper is necessary
to initiate neoplastic transformation. Exam-
ples of gatekeepers include APC for colon
epithelia, RB1 for retinal epithelia, NF1 for
Schwann cells, andVHLfor kidney cells [2,
12]. Inactivation of both homologs of these
genes is found both in hereditary forms of
cancer and in the majority of sporadic can-
cers of the same type. In contrast to gate-
keepers, caretaker genes do not directly
regulate cell growth. Caretaker genes are in-
volved in DNA repair and maintenance of
genomic integrity. Inactivation of a care-
taker does not directly promote tumor for-
mation but facilitates the development of
mutations in gatekeeper genes and other
cancer-related genes. Caretakers, like gate-
keepers, may be tissue-specific, but muta-
tion in a caretaker is neither necessary nor
sufficient for the development of cancer.
Mutations in some caretaker genes cause
human cancer by the two-hit mechanism.
For example, patients with familial breast
cancer syndromes inherit one mutant copy
of BRCA1 or 2, and LOH for the second al-
lele is found in tumors of breast and ovary
[13-16]. Similarly, in hereditary non-poly-
posis colorectal cancer (HNPCC), one mu-
tant copy of mismatch repair genes such as
MLH1, MSH2, or MSH6 is inherited, and
the wild type allele is lost in tumors of the
colon [17]. However, unlike gatekeepers,
mutations in caretakers are uncommon in
sporadic tumors of the types seen in the
hereditary disease [18].
Anumber of human cancer predisposi-
tion syndromes have a recessive mode of in-
heritance (Table 1). These syndromes are
also called genetic instability syndromes,
because one of the hallmarks of these dis-
eases is chromosomal instability and hyper-
sensitivity to various DNA damaging in-
sults. The genes mutated in these diseases,
such as ATM, Fanconi anemia complemen-
tation group, NBS1, Xeroderma pigmento-
sum-associated genes (XPA, XPC, etc.),
BLM, and RECQL4, function in DNAdam-
age sensing or repair [4,8,9] and can be clas-
sified as caretakers by analogy with the
BRCAand HNPCC genes.
Since the identification of the first can-
cer predisposition gene (RB1) in 1986,
tremendous advances have been made in un-
derstanding the function of multiple genes
implicated in both sporadic and hereditary
cancers. However, the mechanism of action
of many more recently identified genes is
not well understood. Further studies are nec-
essary to provide new insights into human
neoplasia and improve the diagnosis and
treatment of both sporadic and hereditary
cancers.
MULTIPLE ENDOCRINE
NEOPLASIA TYPE 1 (MEN1)
Multiple endocrine neoplasia type 1
(MEN1) is an autosomal dominant cancer
predisposition syndrome characterized by
parathyroid, pancreatic islet, and pituitary
tumors as well as other neoplasms such as
gastrinomas, carcinoids, lipomas, angiofi-
bromas, angiomyolipomas and thyroid tu-
mors [19]. Clinical manifestations depend
on the affected organ. Most MEN1-associ-
ated tumors are not metastatic but create
clinical effects by overproduction of hor-
mones such as insulin, glucagon, prolactin,
parathyroid hormone, gastrin, growth hor-
mone, or adrenocorticotropic hormone [19,
20]. The most common manifestation of the
disease is parathyroid adenoma, with pene-
trance reaching almost 100 percent by the
age of 50 [19]. Major causes of morbidity
and mortality in MEN1 are gastrinomas and
foregut carcinoids, which are often highly
metastatic [19].The estimated prevalence of
MEN1 is one in 30,000 [21].
MEN1 was localized to chromosome
11q13 by linkage analysis, and the gene was
later identified by positional cloning [23,
24].Tumors in MEN1 arise through the two-
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one copy of the gene and somatic loss of the
normal allele [22]. Germline mutations in
MEN1 are mainly nonsense or frameshift
and are presumed to cause inactivation of
the gene. The transcript of the MEN1 gene
contains an open reading frame predicted to
encode 610 amino acid proteins.Analysis of
the sequence of the protein menin showed
two nuclear localization signals near the car-
boxyl terminus but has not provided any
other clues to its function. Immunocyto-
chemical studies of interphase somatic cells
show that the protein is located in the nu-
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Table 1. Familial cancer syndromes and cancer predisposition genes [8-9].
Cancer syndrome Type of tumors Gene(s) Function
Dominant mode of inheritance
Familial retinoblastoma Retinoblastoma RB Regulator of cell proliferation
Osteosarcoma
Li-Fraumeni syndrome Soft tissue p53 Transcription factor,
Osteosarcoma DNA damage response
Breast cancer CHK2 [68] Kinase, regulator
Leukemia of p53 activity
Gorlin syndrome Basal cell carcinoma PTCH Transmembrane receptor
for hedgehog
Familial adenomatous Colorectal cancer APC Regulation of ß-catenin
polyposis (FAP)
Hereditary Colorectal cancer MSH2, 6, Mismatch repair
non-polyposis MLH1,
colorectal cancer (HNPCC) PMS1, 2
Neurofibromatosis type 1 Neurofibromas NF1 GAP for p21
Neurofibromatosis type 2 Schwannomas, NF2 Links membraine proteins
Meningiomas to cytoskeleton
Familial breast/ovarian Breast cancer BRCA1/2 DNA repair
cancer syndrome Ovarian cancer
von Hippel-Lindau Renal cancer VHL Transcription elongation factor
syndrome (clear cell)
Hereditary papillary renal Renal cancer MET Transmembrane receptor
cancer (HPRC) (papillary) for HGF
Familial melanoma Melanoma p16 Cyclin-dependent kinases
CDK4 and CDK 6 inhibitor
Multiple endocrine Pituitary Parathyroid MEN1 Transcriptional regulator,
neoplasia type 1 (MEN1) adenoma modulator of AP-1 activity
Pancreatic islet
Multiple endocrine Medullary thyroid RET Transmembrane receptor
neoplasia type 2 (MEN2) cancer
Cowden disease Breast cancer PTEN PI3kinase/AKT inhibitor,
Thyroid cancer phosphatase
Tuberous sclerosis Rabdomyoma TSCI/2 Regulation of cell size and
Renal cancer proliferation through insulin
signalingcleus [25]. Studies in human and mouse
show that MEN1 is expressed widely in
adult and fetal tissues with high levels in the
CNS, lung, liver, kidney, testis, and fetal thy-
mus [23,26-28].
Among the earliest studies of menin
function was a yeast two-hybrid analysis
showing interaction between menin and
JunD, a component of theAP-1 transcription
factor [29]. Studies in mammalian tissue
culture systems showed that the N-terminal
half of menin could inhibit JunD-mediated
transcription. Menin did not bind to other
AP-1 components such as c-Jun, JunB, or
four members of the Fos family. Further in-
vestigation of menin’s involvement in JNK
and other MAPkinase signaling cascades re-
vealed that overexpression of MEN1 in
some cell lines inhibited ERK-mediated
phosphorylation of JunD and Elk1 and JNK-
dependent phosphorylation of JunD and c-
Jun [30]. In addition, overexpression of
menin in CHO-IR cells suppressed insulin-
induced activation of AP-1 and transcrip-
tional induction of c-Fos [31]. Similarly,
menin was shown to bind to and inhibit tran-
scriptional activation by several members of
the NF-ʺB family of transcription factors
[32]. Binding of menin to SMAD3 appears
to enhance transcriptional activation func-
tion, and loss of menin blocksTGF beta sig-
naling [33]. The homeobox-containing
protein Pem [34] has also been shown to
bind menin in biochemical assays. These
data suggest that menin may act as a tran-
scriptional regulator. Our investigations of
the Drosophila MEN1 homolog showed in
vivo interaction of MEN1 with JNK signal-
ing pathway components. We also found
that when tethered to DNA, Drosophila
menin acts as a transcriptional repressor.
Menin does not have any recognizable DNA
binding motifs, and data are conflicting as
to whether menin can directly bind DNA
and whether it binds in a sequence-specific
manner [35,36].
Multiple lines of evidence exist to sup-
port menin’s involvement in transcriptional
control and chromatin modification. Human
menin was found to bind and control the ac-
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Table 1. Familial cancer syndromes and cancer predisposition genes [8-9] (cont.).
Cancer syndrome Type of tumors Gene(s) Function
Recessive mode of inheritance
Bloom syndrome Solid tumors BLM Helicase
DNA repair
Ataxia telangiectasia (AT) Lymphoma ATM DNA repair
DNA damage response
Nijmegen breakage Lymphoma NBS1 Double strand break repair
syndrome (NBS) Glioma
Medulloblastoma
Xeroderma pigmentosum Skin cancer XPB, XPD, XPA Nucleotide excision repair
Rothmund Thompson Basal cell carcinoma RECQL4 Helicase
syndrome Squamous cell
sarcoma
Werner syndrome Oseeosarcoma WRN Helicase
Meningioma
Fanconi anemia Leukemia FANCD2, FANCA DNA repair, DNA
Squamous cancers FANCB, C, FANCE damage response
F, FANCG, L
Abbreviations: GAP – GTPase-activating protein; MSN – mut S homolog; MLH – mut L ho-
molog; PMS – postmeiotic segregation; HGF – hepatocyte growth factor; BRCA – breast can-
cer associated; PTEN – phosphatase and tensin homolog.tivity of multiple transcription factors.
Menin interacts with mSin3a, a component
of the Sin3/Rpd3 HDAC complex [37], and
with a histone methyltransferase complex
containing the trithorax family proteins
MLL2 and Ash2L [38-41]. In addition,
menin was found to bind to the promoter re-
gions of several homeobox genes and to reg-
ulate their expression [38,39]. Genome-wide
analysis of genomic binding sites showed
menin’s localization to the promoters of
multiple genes [42,43]. Recently, two other
transcription targets of menin were identi-
fied. Cyclin-dependent kinase inhibitors
p27kip1 and p18Ink4c are downregulated in
menin-deficient cells, which also exhibited
increased proliferation [40]. Thus, menin
may control cell proliferation through regu-
lating transcription of genes involved in cell
cycle control.
That tumors in MEN1 arise through
two-hit mechanism suggests that menin may
act in the regulation of cell growth or in the
maintenance of genomic integrity, as dis-
cussed above. Several lines of evidence sug-
gest that menin might participate in DNA
damage sensing or repair. Peripheral blood
lymphocytes from MEN1 patients have an
elevated frequency of chromosomal abnor-
malities after exposure to the cross-linking
agent diepoxybutane (DEB) [44]. Menin-
deficient mouse embryonic fibroblasts
(MEFs) are hypersensitive to DEB [45].
Menin interacts with FANCD2, a gene that
underlies the genetic instability syndrome
Fanconi anemia. Moreover, this interaction
is strengthened after the exposure of cells to
ʳ-irradiation [45]. In addition, menin was
shown to interact with replication proteinA
(RPA) [46], a protein that binds single strand
DNA and is important for several DNA re-
pair pathways [47]. Studies from our labo-
ratory show a role for the Drosophila
homolog of MEN1 in maintenance of ge-
nomic integrity. We found that inactivation
of Men1 in Drosophila results in flies that
are sensitive to certain types of DNA dam-
age, in particular to ionizing radiation and
DNA cross-linking agents. In addition,
Men1-deficient flies have an elevated muta-
tion rate both at baseline and after treatment
with ionizing radiation and nitrogen mustard
(a cross-linking agent) [48]. Menin-deficient
tissues from both Drosophila and mammals
fail to undergo S-phase arrest in response to
DNA damage by ionizing radiation [49].
These data suggest that tumor pathogenesis
in the human disease may relate to genomic
instability.
Studies also support a direct role for
MEN1 in the control of cell growth and dif-
ferentiation. Overexpression of menin re-
presses the proliferation and tumorigenesis
of Ras-transformed NIH3T3 cells and in-
sulinoma cells [50]. Data are conflicting as
to whether menin-deficient mouse cells have
increased proliferative capacity. One study
found no cell-autonomous proliferative de-
fects in Men1-/- embryonic stem (ES) cells
or embryonic fibroblasts (MEF) [51]. How-
ever, another study showed that Men1-/-
MEFs have increased proliferative capacity,
and reintroduction of wild type menin sup-
presses their growth, possibly through an in-
teraction with activator of S-phase kinase
(ASK), a component of the Cdc7/ASK ki-
nase complex [52]. Some phenotypes seen
in mouse models of MEN1 suggest a direct
role in growth control. For example, tissue-
specific gene inactivation in pancreatic islet
cells of the mouse leads to widespread hy-
perplasia, consistent with a similar role for
the gene postnatally [53].
Amouse model with targeted disruption
of the Men1 gene showed that menin has an
essential role in development [54]. The phe-
notype of heterozygotes was very similar to
the human MEN1 phenotype with tumors of
the parathyroid, pituitary, pancreatic islets,
thyroid, and adrenal cortex. Homozygous
mice died in utero. They appeared normal at
E9.5 but by E11.5-12.5 were developmen-
tally delayed and smaller than normal litter-
mates.Virtually all fetuses were resorbed by
E14.5. Morphological defects included an
open neural tube, hypoplastic myocardium,
and an extremely malformed liver with ab-
normal organization of the epithelial and
hematopoietic compartments and increased
apoptosis [51]. Conditional knockout of
Men1 in mouse pituitary and pancreatic
islets showed that both these organs were
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deleted in early embryogenesis. Pancreatic
islets developed ß-cell hyperplasia and later,
in six- to 12-month-old mice, pancreatic
islet adenomas. Insulinomas and prolactin-
omas developed in some animals starting at
nine months.The late tumorigenesis in these
mice suggests that additional somatic events
are necessary to promote cancer formation
[53,55].
Two studies suggested a function of
menin related to telomeres. Investigations
in our laboratory [56] showed that menin lo-
calizes to telomeres during meiotic prophase
in mouse spermatocytes. Menin foci were
seen only at this location and not in other re-
gions of meiotic cells. The foci were appar-
ent as soon as axial elements began to form,
and signals increased in intensity throughout
prophase. However, menin did not co-local-
ize with telomeric proteins, such as TRF2,
in somatic cells at any stage of the cell cycle.
Furthermore, telomeres of MEN1-related tu-
mors were no different in length than telom-
eres of histologically similar sporadic
tumors arising without MEN1 mutations.
Overexpression of menin did not influence
telomerase activity as assessed byTRAPas-
says. Another study, which systematically
examined the effects of tumor suppressor
genes on telomere maintenance, suggested
that loss of menin function might stimulate
telomerase (hTERT) expression [57] and
that menin might be involved in tumorigen-
esis through this mechanism.
Menin has also been found to associate
with several cytoskeleton components.
Menin’s interaction with the intermediate
filament proteins GFAP and vimentin was
suggested to control its nuclear import [58].
Another cytoskeletal interactor of menin is
nonmuscle myosin II-Aheavy chain protein,
which was found to co-localize with menin
at the cleavage furrow during cytokinesis
[59].
CONCLUSIONS AND OUTLOOK
In the 10 years since the MEN1 gene
was first cloned, a wealth of information
concerning its possible function in tumori-
genesis has been obtained.The accumulated
genetic and biochemical data show that
menin has multiple binding partners in a
cell. By virtue of interacting with several
transcription factors, menin is proposed to
be involved in signaling pathways such as
JNK, MAPK, TGF beta, and NF-ʺB; all of
which have a well-documented role in can-
cer formation [60-63]. At the same time,
through its role in chromatin modification,
menin has been shown to affect the expres-
sion of c-Fos, hTERT, p27kip1, and p18Ink4c,
which are also linked to neoplastic transfor-
mation [57,60,64,65]. On the cellular level,
menin has been shown to regulate cell cycle
progression and genomic integrity, both of
which are often associated with a cancer
phenotype.
The multiple functions of MEN1 are not
altogether unconnected. As a regulator of
transcription, menin could control the ex-
pression of multiple factors involved in cell
cycle regulation and the DNA damage re-
sponse (see the examples above). The tran-
scription regulation is likely achieved
through menin’s function in chromatin mod-
ification. At the same time, there is a wealth
of evidence connecting the modification of
chromatin with the maintenance of genome
integrity [66]. Finally, the possibilities of
MEN1’s involvement in cell cycle regula-
tion and genome maintenance are not mutu-
ally exclusive. MEN1 was shown to regulate
proper S-phase arrest in response to exoge-
nous DNA damage [49]. Similar regulation
is necessary in the cell as endogenous DNA
damage occurs every cell cycle during DNA
replication [67].
Takentogether, theaccumulated knowl-
edge of MEN1’s potential functions and cel-
lular partners suggests several possible
mechanismsofitsinvolvementincancerfor-
mation. The key question is which of these
functions or interactions play critical role in
cancerdevelopment.Onepossiblewaytoad-
dress this challenging problem is systematic
investigation of tumors obtained from Men1
heterozygous mice as well as from MEN1
patients. One such study generated p18(-/-
)Men1(+/-) and p27(-/-)Men1(+/-) mice and
foundthatp18functionallycollaborateswith
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docrine tumors [64,65]. Another important
question is whether menin aids in the main-
tenanceofgenomeintegritybyregulatingthe
cell cycle or by serving as a structural com-
ponent of DNA repair machinery. To this
end, analysis of mutational spectra could
point to a DNArepair step(s) most deficient
in cells lacking MEN1. Careful examination
of interactions between menin and known
DNA repair proteins is also necessary. Ad-
dressingtheseissuesisofkeyimportancefor
the understanding of MEN1-related carcino-
genesis and for the development of effective
therapeutic approaches.
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